Data investigation

GLP-1 Trial Results Q3 2026: Retatrutide TRIUMPH, Survodutide & Orforglipron ACHIEVE-4

Quarterly digest of GLP-1 and incretin trial results through mid-October 2026: retatrutide TRIUMPH-1 and TRIUMPH-2, survodutide SYNCHRONIZE, orforglipron ACHIEVE-4, Mounjaro's new cardiovascular indication, CagriSema under FDA review, and what comes next.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
14 min read·29 citations

This is the third quarterly digest of GLP-1 receptor-agonist and incretin-multiagonist trial activity. It covers the peer-reviewed Phase 3 readouts, FDA decisions, and trial-registry status changes from late May through mid-October 2026, and keeps a corrected summary of the earlier 2026 readouts below. The quarter’s headline was retatrutide: the TRIUMPH-1 obesity trial was published in the New England Journal of Medicine (mean weight loss of 25.0% at the 12 mg dose at 80 weeks)[16] and TRIUMPH-2 in type 2 diabetes in the Lancet[17]. Survodutide’s first Phase 3 papers landed[19][20], the oral GLP-1 Foundayo (orforglipron) passed its cardiovascular-safety trial[22], and the FDA added a cardiovascular indication to Mounjaro[24]. We refresh this digest each quarter.

Magnitude comparison

Mean percent body-weight change at the highest tested dose in recent GLP-1 / incretin Phase 3 trials, using the treatment-regimen (intention-to-treat style) estimand from each peer-reviewed paper. These are raw arm means, not placebo-adjusted, and the trials differ in length and population, so this is not a head-to-head comparison. ESSENCE was a MASH trial in which weight was a secondary measure.[16][17][19][8][1][7][3]

  • Retatrutide 12 mg (TRIUMPH-1, no diabetes, 80 wk)25.0 % TBWL
    Jastreboff 2026 NEJM; placebo −3.9%
  • Retatrutide 12 mg (TRIUMPH-2, type 2 diabetes, 80 wk)18.8 % TBWL
    Bellido 2026 Lancet; placebo −5.1%
  • CagriSema (REDEFINE 2, type 2 diabetes, 68 wk)13.7 % TBWL
    Davies 2025 NEJM; placebo −3.4%
  • Survodutide 6.0 mg (SYNCHRONIZE-1, no diabetes, 76 wk)13.0 % TBWL
    le Roux 2026 NEJM; placebo −5.4%
  • Foundayo — orforglipron 36 mg (ATTAIN-1, 72 wk)11.2 % TBWL
    Wharton 2025 NEJM; placebo −2.1%
  • Wegovy — semaglutide 2.4 mg (ESSENCE MASH, 72 wk)10.5 % TBWL
    Sanyal 2025 NEJM; placebo −2.0%
  • Foundayo — orforglipron 36 mg (ATTAIN-2, type 2 diabetes, 72 wk)9.6 % TBWL
    Horn 2026 Lancet; placebo −2.5%
Mean percent body-weight change at the highest tested dose in recent GLP-1 / incretin Phase 3 trials, using the treatment-regimen (intention-to-treat style) estimand from each peer-reviewed paper. These are raw arm means, not placebo-adjusted, and the trials differ in length and population, so this is not a head-to-head comparison. ESSENCE was a MASH trial in which weight was a secondary measure.

Q3 2026 Phase 3 readouts (late May to mid-October)

TRIUMPH-1 (retatrutide, obesity without diabetes)

Published: N Engl J Med, online September 29, 2026[16]; Eli Lilly first announced topline results on May 21, 2026.
Registry: NCT05929066, status COMPLETED (primary completion April 6, 2026)[15].
Design: phase 3, randomized, double-blind, 80-week trial of once-weekly retatrutide 4, 9 or 12 mg versus placebo in 2,339 adults with obesity and no diabetes, with knee-osteoarthritis and obstructive-sleep-apnea substudies built in[9].
Result: mean weight change was −17.6% (4 mg), −23.7% (9 mg) and −25.0% (12 mg) versus −3.9% with placebo on the treatment-regimen estimand. Retatrutide also reduced knee-pain scores in the 574 participants with knee osteoarthritis and cut apnea-hypopnea events in the 243 with sleep apnea. Gastrointestinal effects were the most common adverse events[16]. The widely quoted “28.3%” figure is Lilly’s efficacy-estimand number for the 12 mg dose, not the journal’s primary analysis.

TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (cardiovascular disease)

TRIUMPH-2 was published in the Lancet(online September 29, 2026)[17]. In 1,152 adults with obesity and type 2 diabetes, mean weight change at 80 weeks was −11.9% (4 mg), −16.8% (9 mg) and −18.8% (12 mg) versus −5.1% with placebo (treatment-regimen estimand). Treatment discontinuation for adverse events or death was 12% on 9 mg and 8% on 12 mg versus 5% on placebo, and hypotension and dysesthesia were more frequent on retatrutide[17]. As with every incretin, weight loss is smaller in diabetes than without it.
TRIUMPH-3 (NCT05882045) randomized 1,949 adults (Lilly) with severe obesity (BMI ≥35) and established cardiovascular disease. Lilly’s July 23, 2026 topline release reported mean weight loss of 21.6% (9 mg) and 22.6% (12 mg) versus 3.2% on placebo at 80 weeks on the efficacy estimand[18]. It is a weight-loss trial in a cardiovascular population, not a cardiovascular-outcomes trial, and it has no peer-reviewed paper yet. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027[18].

SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD (survodutide)

Boehringer Ingelheim’s GLP-1/glucagon dual agonist survodutide produced its first Phase 3 papers this quarter[10].
SYNCHRONIZE-1 (NCT06066515; N Engl J Med, online June 7, 2026): in 725 adults with obesity and no diabetes, weight change at 76 weeks was −12.2% (3.6 mg) and −13.0% (6.0 mg) versus −5.4% with placebo. Gastrointestinal adverse events occurred in 80.9% and 89.7% of the survodutide groups versus 47.9% on placebo[19].
SYNCHRONIZE-2 (NCT06066528; N Engl J Med, online October 1, 2026): in 752 adults with obesity and type 2 diabetes, weight change at 76 weeks was −8.2% and −9.8% versus −3.9% with placebo, with HbA1c falling about 0.8–0.9 percentage points from a 7.4% baseline[20].
SYNCHRONIZE-MASLD (Nat Med, online June 7, 2026): in 216 adults with obesity and at-risk fatty liver disease, 68.5% of survodutide-treated participants versus 28.6% on placebo had at least a 30% reduction in liver fat at 48 weeks on the treatment-regimen estimand[21].
Read-across: survodutide’s weight loss so far sits below tirzepatide and retatrutide, and its gastrointestinal burden is high. Its liver data are the more distinctive part of the program.

ACHIEVE-4 (orforglipron cardiovascular safety)

Published: Lancet, online September 30, 2026[22]. Registry NCT05803421, status COMPLETED[15].
Design: open-label, event-driven trial of orforglipron versus titrated insulin glargine in 2,749 adults with type 2 diabetes, overweight or obesity, and established cardiovascular or chronic kidney disease.
Result: over a median of 2 years, the four-component MACE outcome occurred in 4.2% on orforglipron versus 5.0% on insulin glargine (HR 0.84; 95% CI 0.59–1.20), meeting the pre-set non-inferiority margin of 1.8. Gastrointestinal adverse events were far more common on orforglipron (62.1% vs 14.2%), while clinically significant hypoglycemia was less common (6.8% vs 19.2%)[22]. This is a safety result, not proof of cardiovascular benefit: the confidence interval crosses 1, and the comparator was insulin, not placebo. Foundayo’s US label is still for chronic weight management only[11].

Earlier 2026 readouts (from the Q2 digest)

ATTAIN-MAINTAIN (orforglipron)

Published: May 13, 2026, Nature Medicine[2]. Registry NCT06584916, status COMPLETED[15].
Design: double-blind, placebo-controlled phase 3b trial in people who had already lost weight on injectable tirzepatide (cohort 1, n = 205) or semaglutide (cohort 2, n = 171) in the SURMOUNT-5 study. They were randomized to switch to once-daily orforglipron or to placebo for 52 weeks.
Result: people switched from tirzepatide to orforglipron kept an estimated 74.7% of their earlier weight reduction versus 49.2% on placebo; people switched from semaglutide kept 79.3% versus 37.6%[2]. The takeaway: a pill can hold most, but not all, of the weight lost on an injection, and stopping treatment altogether leads to substantial regain.

ATTAIN-2 (orforglipron in type 2 diabetes)

Published: Lancet, online November 20, 2025[3]. Registry NCT05872620, status COMPLETED[15].
Design: 72-week, double-blind trial of orforglipron 6 mg, 12 mg or 36 mg versus placebo in 1,613 adults with type 2 diabetes and overweight or obesity.
Result: mean weight change was −9.6% at 36 mg versus −2.5% with placebo, smaller than the −11.2% seen in non-diabetic ATTAIN-1[1], which fits the class pattern of less weight loss in diabetes. HbA1c improved significantly. These two trials underpin the oral, non-injectable option Foundayo, approved April 1, 2026[14].

SURMOUNT-OSA secondary outcomes (tirzepatide)

Published: January 2026 online, Nature Medicine[5]. A pre-specified secondary analysis of the SURMOUNT-OSA trial[4] reporting reductions in blood pressure and hsCRP and improvements in lipid and glycemic markers alongside the apnea-hypopnea-index benefit that supports Zepbound’s sleep-apnea indication[13].

Retatrutide lipid & metabolite profiles

An exploratory analysis of the Phase 2 retatrutide trial[29] in J Clin Endocrinol Metab[28] found broad favorable shifts in lipid and metabolite profiles that tracked with the amount of weight lost. It is not a Phase 3 readout; the Phase 3 TRIUMPH results are covered above.

Trial registry status

Status and primary-completion dates below were checked against the ClinicalTrials.gov v2 API in October 2026[15].

NCT ID / trialDrugPrimary completionRegistry statusResults
NCT05929066 (TRIUMPH-1)Retatrutide2026-04-06COMPLETEDNEJM, Sept 2026
NCT05929079 (TRIUMPH-2, T2D)Retatrutide2026-06-16COMPLETEDLancet, Sept 2026
NCT05882045 (TRIUMPH-3, CV disease)Retatrutide2026-04-16COMPLETEDTopline press release only (July 2026)
NCT06066515 (SYNCHRONIZE-1)Survodutide2025-12-02COMPLETEDNEJM, June 2026
NCT06066528 (SYNCHRONIZE-2, T2D)Survodutide2025-12-12COMPLETEDNEJM, Oct 2026
NCT06309992 (SYNCHRONIZE-MASLD)Survodutide2025-10-09COMPLETEDNat Med, June 2026
NCT06077864 (SYNCHRONIZE-CVOT)Survodutide2026-06-01COMPLETEDNot yet published
NCT05803421 (ACHIEVE-4)Orforglipron2026-03-16COMPLETEDLancet, Sept 2026
NCT05869903 (ATTAIN-1)Orforglipron2025-07-25ACTIVE, NOT RECRUITINGNEJM, 2025
NCT05872620 (ATTAIN-2)Orforglipron2025-08-08COMPLETEDLancet, 2025
NCT06584916 (ATTAIN-MAINTAIN)Orforglipron2025-11-21COMPLETEDNat Med, May 2026
NCT06858839 (MARITIME-1)Maridebart cafraglutide (MariTide)2027-01-21 (estimated)ACTIVE, NOT RECRUITINGPending

FDA approvals + label updates

Mounjaro (tirzepatide) — cardiovascular indication

Approved: August 2026 (Lilly announced it August 28, 2026)[24]. The Mounjaro label now includes reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events[25].
Evidence: SURPASS-CVOT, a head-to-head trial of tirzepatide versus dulaglutide in 13,165 patients with type 2 diabetes and atherosclerotic cardiovascular disease. The primary outcome occurred in 12.2% versus 13.1% (HR 0.92; 95.3% CI 0.83–1.01): non-inferior, but not statistically superior[23]. This indication is for Mounjaro in type 2 diabetes; it is not a Zepbound weight-management indication.

Foundayo (orforglipron) — approved April 1, 2026

FDA approved Foundayo (NDA 220934) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition — the first oral small-molecule GLP-1 receptor agonist for this use[14]. A labeling supplement followed on August 4, 2026, and the DailyMed label was last re-published August 13, 2026[11]. Pivotal evidence: ATTAIN-1[1] and ATTAIN-2[3].

Wegovy (semaglutide) — 7.2 mg dose and oral tablet

Wegovy injection (NDA 215256) received an efficacy supplement on March 19, 2026, plus labeling and manufacturing supplements through June 2026[14]. The current label lets patients who tolerate 2.4 mg for at least 4 weeks increase to a maximum of 7.2 mg once weekly, and lists the injection and the oral tablet (NDA 218316, approved December 22, 2025) under one label, last re-published June 30, 2026[12].

Zepbound (tirzepatide) — label refresh

Zepbound (NDA 217806) received an efficacy supplement on August 26, 2026, and its DailyMed label was re-published September 2, 2026[14][13]. The indications section still lists two uses: chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity[13]. Heart failure with preserved ejection fraction is not a labeled indication, even though the SUMMIT trial was positive[6].

CagriSema — under FDA review

Novo Nordisk submitted a New Drug Application for once-weekly CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) for weight management on December 18, 2025[26]. As of mid-October 2026 we found no FDA decision and no CagriSema label on DailyMed.

Null and negative readouts

Two results in 2026 fell short of what their sponsors were aiming for, and our Q2 edition missed the first:

  1. REDEFINE 4 (CagriSema vs tirzepatide). In this 84-week, open-label head-to-head trial, CagriSema did not meet its primary endpoint of non-inferiority to tirzepatide 15 mg on weight loss. Weight loss was 20.2% versus 23.6% on the treatment-regimen estimand (23.0% vs 25.5% if everyone had stayed on treatment), per Novo Nordisk’s February 23, 2026 announcement[27].
  2. SURPASS-CVOT superiority. Tirzepatide met non-inferiority versus dulaglutide but missed statistical superiority (P = 0.09)[23]. That was enough for a cardiovascular-risk indication, but not for a claim that tirzepatide beats dulaglutide on heart outcomes.

Two interpretive caveats carry over. First, orforglipron loses less weight in type 2 diabetes (~9.6%) than without it (~11.2%)[3][1], and the same gap now shows up for retatrutide and survodutide[17][20]. Second, ATTAIN-MAINTAIN shows that stopping treatment leads to regain[2]: GLP-1 therapy, oral or injectable, is chronic, not curative.

Pipeline tracker: what’s next

Late-stage programs and their next milestones, as of mid-October 2026[15].

DrugSponsorMechanismWhere it standsNext milestone
RetatrutideEli LillyGLP-1 + GIP + glucagon triple agonistTRIUMPH-1 (NEJM) and TRIUMPH-2 (Lancet) published; TRIUMPH-3 topline onlyFDA submission planned Q1 2027[18]
SurvodutideBoehringer Ingelheim / Zealand PharmaGLP-1 + glucagon dual agonistSYNCHRONIZE-1, -2 and -MASLD publishedSYNCHRONIZE-CVOT results (completed June 2026)
CagriSemaNovo NordiskAmylin analog + GLP-1 (cagrilintide + semaglutide)NDA submitted December 2025[26]; see deep-diveFDA decision (no date confirmed)
MariTide (maridebart cafraglutide)AmgenGLP-1 agonist + GIP receptor antagonist (antibody-peptide conjugate)NCT06858839 (MARITIME-1) active, not recruitingPrimary completion January 2027 (estimated)
Orforglipron (type 2 diabetes)Eli LillyOral small-molecule GLP-1 agonistACHIEVE-4 cardiovascular safety publishedNo US type 2 diabetes indication yet

Frequently Asked Questions

In TRIUMPH-1 (published in the New England Journal of Medicine in September 2026), 2,339 adults with obesity and no diabetes took retatrutide or placebo for 80 weeks. Mean weight change was −17.6% on 4 mg, −23.7% on 9 mg and −25.0% on 12 mg versus −3.9% on placebo. Retatrutide also reduced knee-osteoarthritis pain and sleep-apnea events in the trial’s substudies. It is still investigational; Lilly plans to file with the FDA in the first quarter of 2027.
The main peer-reviewed Phase 3 papers from late May to mid-October 2026 were TRIUMPH-1 (retatrutide, NEJM), TRIUMPH-2 (retatrutide in type 2 diabetes, Lancet), SYNCHRONIZE-1 and SYNCHRONIZE-2 (survodutide, NEJM), SYNCHRONIZE-MASLD (survodutide, Nature Medicine) and ACHIEVE-4 (orforglipron cardiovascular safety, Lancet). TRIUMPH-3 reported topline results by press release only.
Yes. In REDEFINE 4, announced February 23, 2026, CagriSema did not meet its primary endpoint of non-inferiority to tirzepatide 15 mg on weight loss (20.2% vs 23.6% on the treatment-regimen estimand). Separately, SURPASS-CVOT showed tirzepatide was non-inferior to dulaglutide on cardiovascular events but did not prove superiority.
In ACHIEVE-4 (Lancet, 2026), orforglipron was non-inferior to insulin glargine for major cardiovascular events in 2,749 adults with type 2 diabetes and heart or kidney disease (4.2% vs 5.0%; hazard ratio 0.84, 95% CI 0.59–1.20). That establishes cardiovascular safety, not proven benefit. Gastrointestinal side effects were much more common than with insulin.
The FDA approved Foundayo (orforglipron, NDA 220934) on April 1, 2026 for chronic weight management in adults with obesity, or overweight plus a weight-related condition. It is the first oral small-molecule GLP-1 receptor agonist approved for this use. It does not yet have a US type 2 diabetes indication.
No. As of the Zepbound label re-published on DailyMed on September 2, 2026, its indications are chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. The SUMMIT heart-failure trial was positive, but heart failure is not a labeled use. The new cardiovascular indication approved in August 2026 belongs to Mounjaro, for adults with type 2 diabetes at high cardiovascular risk.

References

  1. 1.Wharton S, Aronne LJ, Stefanski A, et al.; ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. PMID: 40960239.
  2. 2.Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PMID: 42120723.
  3. 3.Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026. PMID: 41275875.
  4. 4.Malhotra A, Grunstein RR, Fietze I, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. PMID: 38912654.
  5. 5.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026. PMID: 41540105.
  6. 6.Packer M, Zile MR, Kramer CM, et al.; SUMMIT Trial Investigators. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025. PMID: 39555826.
  7. 7.Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025. PMID: 40305708.
  8. 8.Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. PMID: 40544432.
  9. 9.Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PMID: 41090431.
  10. 10.Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, et al. Optimization of patient and site engagement in the SYNCHRONIZE phase 3 clinical trial program for survodutide in obesity through clinical trial simulation. Contemp Clin Trials Commun. 2026. PMID: 41704810.
  11. 11.Lilly USA, LLC. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information. Initial U.S. Approval: 2026. DailyMed (NIH); FDA NDA 220934, approved April 1, 2026; last published August 13, 2026. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  12. 12.Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet — US Prescribing Information. DailyMed (NIH); last published June 30, 2026. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  13. 13.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, solution; ZEPBOUND KwikPen — US Prescribing Information. DailyMed (NIH); last published September 2, 2026. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  14. 14.U.S. Food and Drug Administration. Drugs@FDA structured submission records — FOUNDAYO (NDA 220934), WEGOVY (NDA 215256, NDA 218316), ZEPBOUND (NDA 217806) and MOUNJARO (NDA 215866) submission histories. openFDA Drugs@FDA. 2026. https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:%22FOUNDAYO%22
  15. 15.U.S. National Library of Medicine. ATTAIN-1 (NCT05869903), ATTAIN-2 (NCT05872620), ATTAIN-MAINTAIN (NCT06584916), ACHIEVE-4 (NCT05803421), TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), SYNCHRONIZE-1 (NCT06066515), SYNCHRONIZE-2 (NCT06066528), SYNCHRONIZE-MASLD (NCT06309992), SYNCHRONIZE-CVOT (NCT06077864), MARITIME-1 (NCT06858839) — registry status and primary completion dates from the v2 API. ClinicalTrials.gov v2 API. 2026. https://clinicaltrials.gov/api/v2/studies/NCT05929066
  16. 16.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  17. 17.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  18. 18.Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3 topline results). PR Newswire, July 23, 2026. 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
  19. 19.le Roux CW, et al.; SYNCHRONIZE-1 Investigators. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. PMID: 42253238.
  20. 20.Wharton S, le Roux CW, Startseva E, et al.; SYNCHRONIZE-2 Investigators. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. 2026. PMID: 42820639.
  21. 21.Kaplan LM, Startseva E, le Roux CW, Wharton S, et al.; SYNCHRONIZE-MASLD Investigators. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026. PMID: 42252333.
  22. 22.Klein KR, Wysham C, Tuttle KR, Davies MJ, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026. PMID: 42815506.
  23. 23.Nicholls SJ, et al.; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. PMID: 41406444.
  24. 24.Eli Lilly and Company. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. PR Newswire, August 28, 2026. 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html
  25. 25.Eli Lilly and Company. MOUNJARO (tirzepatide) injection, solution; MOUNJARO KwikPen — US Prescribing Information. DailyMed (NIH); last published September 2, 2026. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  26. 26.Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. PR Newswire, December 18, 2025. 2025. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
  27. 27.Novo Nordisk A/S. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved. Novo Nordisk company announcement, February 23, 2026. 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501
  28. 28.Pearson MJ, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195.
  29. 29.Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Anchor reading for the broader GLP-1 landscape and each pipeline drug in this digest:

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $250/mo (starting dose)

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $149/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo (2-month plan rate)

Get started →